Related Technologies - University of Pittsburgh

Search text

About 24 results

(0.11 seconds)

T Cell Receptors Targeting Mutations in RNA Splicing Factors

04989

RNA splicing is a fundamental process in eukaryotes in which messenger RNA is prepared to be translated into a protein.

Cancer patients with similar mutations stand to benefit greatly from personalized immunotherapy focused on genetically engineering human T cells with TCRs targeted to this mutated RNA splicing factor.

Pitt researchers isolated genes encoding two unique T cell receptors (TCRs) capable of recognizing peptide epitopes from a mutated RNA splicing factor commonly found in uveal melanoma, chronic lymphocytic leukemia, myelodysplastic syndromes, and breast cancer.

Therapeutic Modality

Cell Therapy - T Cell

Immunology Oncology

Leukemia Ocular cancer Breast cancer

Immuno-oncology

Udai Kammula

Med-Surgery

2019-05-10

Extracellular Matrix of Primitive Animal Species

03728

This unique biological cue not only augments in vitro cell proliferation and migration under stress conditions but also translates into tangible in vivo improvements, setting a new benchmark for regenerative interventions in non-regenerative mammalian organs.

The approach harnesses both normal and healing zebrafish cardiac ECM sources, which provide essential structural components like collagen, elastin, and glycosaminoglycans, while retaining natural regenerative signals.

What differentiates this approach is its strategic departure from traditional mammalian ECM sources by leveraging the innate regenerative capabilities of zebrafish tissue.

Life Science Research Tool

Other Life Science Research Tool

Cardiovascular

Myocardial infarction

Yadong Wang

Bioengineering

2015-09-19

RNA- and DNA-Based Assays for Predicting Paclitaxel Resistance in Triple Negative Breast Cancer

05224

RNA- and DNA-based assays for this gene fusion can be used to predict paclitaxel resistance in triple negative breast cancer and allow treatment providers to quickly pivot to alternative treatment options, sparing the patient from the unnecessary and unpleasant side effects of chemotherapy, in addition to serving as a target for novel therapeutics.

While the complexity of genomic rearrangements in this cancer has obscured the role that gene fusions play in the pathology of TNBC, researchers at the University of Pittsburgh identified 99 recurrent gene fusions, 57% of which are cryptic adjacent gene rearrangements (AGRs).

2020-01-17

Hydractinia RNA as a Research Tool